Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL6500935 | 1.00 | KDM4E (0.34) | KDM4EAPAF1NSD2MAPTGPR3 | |
| SCHEMBL6417725 | 0.86 | CYP2D6 (0.40) | KDM4EAPAF1NSD2MAPTCYP2D6 | |
| SCHEMBL6417722 | 0.86 | CYP2D6 (0.40) | KDM4EAPAF1NSD2MAPTCYP2D6 | |
| SCHEMBL8516718 | 0.86 | CYP2D6 (0.40) | KDM4EAPAF1NSD2MAPTCYP2D6 | |
| Hydrochloric Acid SCHEMBL8143807 | 0.85 | CYP17A1 (0.40) | KDM4ECYP2D6CYP17A1 | |
| Hydrochloric Acid SCHEMBL8150974 | 0.85 | CYP17A1 (0.40) | KDM4ECYP2D6CYP17A1 | |
| SCHEMBL30745623 | 0.84 | CYP17A1 (0.37) | KDM4ECYP2D6CYP17A1 | |
| Oxalic Acid SCHEMBL20895674 | 0.82 | ALDH1A1 (0.36) | MAPTCYP2D6CYP17A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL20502732 | 0.75 | GPR3 (0.36) | MAPTGPR3KCNH2ACHE | |
| SCHEMBL924657 | 0.73 | MAPT (0.32) | KDM4EAPAF1NSD2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050240025-A1 | Method for producing imidazolium salts | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240025-A1 | Method for producing imidazolium salts | TPMT, MPST, INMT | KDM4E 2145/4885APAF1 3714/4885NSD2 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.